Advances in synthetic biology have enabled production of a variety of compounds using 13 bacteria as a vehicle for complex compound biosynthesis. Violacein, a naturally occurring 14 indole pigment with antibiotic properties, can be biosynthetically engineered in Escherichia 15 coli expressing its non-native synthesis pathway. To explore whether this synthetic 16 biosynthesis platform could be used for drug discovery, here we have screened bacterially-17 derived violacein against the main causative agent of human malaria, Plasmodium 18 falciparum. We show the antiparasitic activity of bacterially-derived violacein against the P. 19 falciparum 3D7 laboratory reference strain as well as drug-sensitive and resistant patient 20 isolates, confirming the potential utility of this drug as an antimalarial. We then screen a 21 biosynthetic series of violacein derivatives against P. falciparum growth. The demonstrated 22
varied activity of each derivative against asexual parasite growth points to potential for 23 further development of violacein as an antimalarial. Towards defining its mode of action, we 24
show that biosynthetic violacein affects the parasite actin cytoskeleton, resulting in an 25 accumulation of actin signal that is independent of actin polymerization. This activity points 26 to a target that modulates actin behaviour in the cell either in terms of its regulation or its 27 folding. More broadly, our data show that bacterial synthetic biosynthesis is a suitable 28 platform for antimalarial drug discovery with potential applications in high-throughput and 29 cost-effective drug screening with otherwise chemically-intractable natural products. 30 31 KEYWORDS 32 Violacein; drug discovery; synthetic biology; antimalarial 33
INTRODUCTION 35
Malaria has a huge global health burden, with around half of the world's population at risk 36 of contracting the disease which killed over 400 000 people in 2017 1 . Malaria disease is 37 caused by apicomplexan parasites from the genus Plasmodium, with Plasmodium 38 falciparum causing the majority of deaths worldwide. The symptoms of malaria disease 39 develop during the asexual stages of the parasite life cycle, which occurs in the blood 40 stream. Here, the parasite undergoes multiple rounds of growth, replication and invasion of 41 red blood cells. Various drugs have been developed to target the asexual stages of the 42 parasite but, inevitably, resistance has evolved to every major front-line therapy for malaria 43 treatment including, most recently, artemisinin combined therapies (ACTs) 2 . Multi-drug 44 resistance to ACTs, focussed in the Greater Mekong Subregion of South East Asia, has been 45 reported both as delayed parasite clearance and, more worryingly, treatment failure 3 . The 46 challenges of emerging drug resistance combined with the cost associated with 47 development of new drugs make it essential to explore new ways to develop novel 48 antimalarial compounds. 49 50 Previous work identified violacein, a violet indolocarbazole pigment produced by bacteria 51 (Fig. 1a ), as a potential antimalarial able to kill both asexual P. falciparum parasites in vitro 52 and protect against malaria infection in a mouse malaria model in vivo 4-6 . Violacein's 53 antimalarial activity has therefore identified it as a potential for future drug development. 54 However, commercial violacein samples can only be obtained through laborious purification 55 from bacteria (Chromobacterium 7, 8 or Janthinobacterium 9 ) because of the complexity of its 56 highly aromatic structure ( Fig. 1a ). Purification from these bacteria requires specialised 57 equipment and high-level biosafety equipment since these bacteria themselves can cause 58 deadly infections 10 . As such, commercially available violacein is extremely expensive. 59
Alternative strategies of violacein synthesis are being explored, in particular the use of 60 synthetic biology to engineer industrial bacterial species that can express non-native 61 violacein. Several groups including ours 11 have been successful in implementing a five-gene 62 violacein biosynthetic pathway (vioABCDE) into Escherichia coli or other heterologous 63 hosts 12-14 , providing a route for robust, in-house and inexpensive compound production. 64
We have previously extended the success of this biosynthetic pathway by generating 66 combinations of 68 new violacein and deoxyviolacein analogues. These combinations are 67 achieved by feeding various tryptophan substrates to recombinant E. coli expressing the 68 violacein biosynthetic pathway or via introduction of an in vivo chlorination step -the 69 tryptophan 7-halogenase RebH from the rebeccamycin biosynthetic pathway 13, [15] [16] [17] . This 70 biosynthetic approach is able to produce large quantities of compound derivatives using 71 simple, cheap and non-hazardous bacteria compared to native producing strains in a 72 sustainable and flexible approach. 73 74 Here, we set out to explore whether use of this biosynthetic system could be developed as a 75 route to antimalarial compound production and testing, measuring the activity of 76 derivatives on the growth of P. falciparum sexual and asexual parasites. We have confirmed 77 the viability of the system, ensuring there is no background antiparasitic activity in bacterial 78 solvent extracts lacking violacein. We then tested the biosynthetic violacein extract from E. 79 coli and confirmed its half maximal inhibitory concentration (IC50) in agreement with a 80 commercial violacein standard and previous studies 14 . Finally, as well as using this approach 81 to explore the mode of action of violacein, we show that extracts representing a diverse 82 series of biosynthetically derived variants show varying effects on parasite growth, with 16 83 of the 28 compound mixtures inhibiting growth to a greater level than the parent violacein 84 molecule. Indeed, one purified compound, 7-chloroviolacein, exhibits a ~20% higher 85 inhibition activity than the underivatized violacein compound. The high-throughput 86 approach used in this study suggests that biosynthetic systems may therefore provide an, as 87 yet, untapped resource for screening complex compounds and optimising them for 88 antimalarial discovery. 89
RESULTS 91
Violacein expressed using synthetic operons kills P. falciparum 3D7 parasites 92
Previous work has shown that violacein is able to kill asexual P. falciparum parasites in 93 vitro 9,13 but noted erythrocytic rupture at concentrations above 10 µM and a cytotoxic IC50 94 of 2.5 µM. Taking this into consideration, we used concentrations of 2 µM violacein or less 95 to explore growth inhibition of P. falciparum asexual stages, noting no phenotypic effect on 96 erythrocyte morphology at the highest final concentration (Fig. S1 ). Our biosynthetic system 97 for violacein production requires chloramphenicol drug pressure, which is known to affect 98 parasite viability 18 . We first set out to ensure presence of this known antibiotic did not 99 affect parasite growth. Extract from bacteria lacking the violacein producing enzymes but 100 grown under chloramphenicol pressure (i.e. background) did not affect parasite viability 101 ( Fig. S2 ). This gave us confidence that extracts from biosynthetically modified E. coli would 102 report only on the activity of a drug produced but not from background chloramphenicol 103 contamination. To test this, we compared the activity of a commercial violacein standard 104 (Vio-Sigma) with violacein derived from bacterial solvent extracts from E. coli biosynthesis 105 (Vio-Biosyn) on wild-type 3D7 P. falciparum growth, using a well-established asexual growth 106 inhibition assay. No difference in the IC50 values between the two violacein samples was 107 seen . We further tested the two violacein samples on sexual parasites by 108 measuring exflagellation 19 and saw no difference in the IC50 values of around 1.7 µM (Fig. 109 S3) but complete IC50 curves could not be generated without going above the cytotoxic 110 threshold of 2.5 µM. All these data demonstrate that solvent extracted violacein from E. 111 coli, Vio-Biosyn, is active and that its production provides a suitable platform for 112 development and testing of potential antimalarial compounds. 113 114
Biosynthetic violacein extract kills both artemisinin-resistant and -sensitive field isolate 115 parasites 116
To explore whether violacein has utility for addressing emerging ACT drug resistance in the 117 field, we tested the efficacy of Vio-Sigma and Vio-Biosyn on two parasite clinical isolates 118 deriving from the Greater Mekong subregion, where ACT resistance is concentrated. Both 119 clinical isolates have been phenotypically characterised in clinic, showing either treatment 120 failure or success, adapted to culture and genotyped for the C580Y Kelch-13 resistance 121 marker 20 known to correlate with sensitivity to artemisinin-based drugs. Both the artemisinin-sensitive isolate (ANL1, Kelch13 wild-type) and the artemisinin-resistant isolate 123 (APL5G, Kelch13 C580Y) were sensitive to Vio-Biosyn and Vio-Sigma with similar IC50 values 124 . Activity against artemisinin-resistance provides support for development of the 125 violacein scaffold for addressing emerging drug-resistance in the field. 126 127
Violacein derivatives show potent anti-malarial activity 128
To explore whether bacterial biosynthesis could be utilised further to generate compound 129 derivatives, increasing the throughput of complex molecule testing, we obtained extracts 130 from 28 bacteria strains each modulated to synthesise a mixture of violacein analogues ( Fig.  131 S4) 21 . The bacterial extracts were produced by feeding corresponding tryptophan substrates 132 as described previously 14 and violacein concentrations in the extracts were calibrated 133 against a violacein standard. Asexual growth assays were again carried out, testing each 134 extract at the IC50 of biosynthetic violacein, 0.50 µM. We saw a large variation of inhibition 135 of parasite growth, with 8 compound mixtures exhibiting >95% inhibition, whilst 12 others 136 showed a decreased effect on parasite growth (Fig. 3a) . As a proof-of-concept, one of the 137 more active extracts was used to purify the violacein derivative, 7-chloroviolacein ( Fig. 3b ). 138 7-chloroviolacein exhibited a decrease in IC50 from 0.51 µM (violacein) to 0.42 µM (7-139 chloroviolacein) (Fig. 3c) . The speed and low cost of extracting these violacein analogues 140 and purifying them directly from bacteria suggests an entirely new approach to complex 141 compound drug-testing for antimalarial discovery and optimisation. 142 143
Biosynthetic violacein affects actin dynamics in the cell but does not affect polymerisation 144 in vitro 145
The mode of action of violacein against P. falciparum parasites has not previously been 146 characterised. Towards exploring the phenotype associated with its activity we performed 147 flow cytometry and immunofluorescence assays (IFAs) to observe any changes in the 148 parasite under biosynthetic violacein treatment. A 3D7-derived parasite line expressing a 149 constitutive cytoplasmic green fluorescent protein (sfGFP) marker was labelled with DNA 150 marker DAPI (4′,6-diamidino-2-phenylindole) and a monoclonal antibody that preferentially 151 recognises filamentous actin 22,23 to explore overall parasite morphology: cytoplasm, nucleus 152 and actin cytoskeleton respectively. Parasites were then treated with either negative, 153 dimethyl sulfoxide (DMSO), or positive, actin filament stabilising compound, jasplakinolide (JAS) controls as well as Vio-Biosyn. Parasites were checked by flow cytometry for any 155 differences in overall signal (Fig. S5) . A low actin-positive signal was seen with DMSO 156 treatment, as expected given the predominance of short, transient filaments and globular 157 actin in asexual parasites 24 . The intensity of actin labelling following JAS and violacein 158 treatment both, however, showed marked increases when compared to DMSO (Fig. S5) . 159 160 To explore the nature of flow-cytometry changes in actin intensity following violacein 161 treatment, IFAs were undertaken. In the DMSO-treated parasites, the GFP signal is spread 162 throughout the cytoplasm along with a clearly defined nucleus as expected (Fig. 4a ). The 163 actin signal is diffuse with a low background (Fig. 4a ). Following JAS treatment, actin 164 filaments are known to be stabilised 24 producing an expected concentrated overall actin 165 signal (Fig. 4b) , indicative of high local concentrations of polymerized actin. Parasites 166 treated with Vio-Biosyn also gave a much higher actin signal than untreated controls, 167 though distinct from that following JAS treatment (Fig. 4c) . The concentrated signal from 168
Vio-Biosyn was broader across the cell and less focussed in localised regions of the cell 169 periphery. This matched the overall intensity of signal seen by flow-cytometry and relative 170 to sfGFP signal as a control for parasite size (Fig. 4d ). In the DMSO-treated control, the 171 diffuse actin signal is 3% of total GFP signal. This increases to 27% upon JAS treatment, 172
indicative of an increased number of filaments, whereas parasites treated with Vio-Biosyn 173 reach a mean average signal 98%, representing a huge increase in actin accumulation in the 174 cell. This broad concentration of actin signal would be indicative of either massively 175 increased filament nucleation or actin aggregation as caused by actin misfolding. To test 176 whether Vio-Biosyn directly affects actin filament formation (as JAS does), both drugs were 177 assayed using a pyrene-labelled actin assembly assay, used previously to test compound 178 derivatives for actin activity 24 . No effect on actin polymerisation was seen with Vio-Biosyn 179 when compared to either JAS (filament nucleating) or the monomer-stabilising drug 180 latrunculin B (Fig. 4d ). Together, these observations suggest Vio-Biosyn does not directly 181 interact with actin. It is therefore possible that Vio-Biosyn interacts with actin indirectly such 182 as via the known actin-binding partners in the parasite cell 25 or via an alternative pathway 183 involved in actin folding, which would give rise to actin aggregation within the cell. 184
185

DISCUSSION 187
The emergence of resistance to front-line artemisinin-based drug treatments for malaria is a 188 major threat to global health. As such, new antimalarial treatments are in urgent demand. 189
Here, we tested violacein, a compound with known antibacterial, antitumorigenic and 190 antiparasitic activity, against P. falciparum parasites validating its potential utility for 191 antimalarial drug development. We showed that biosynthetically produced violacein was as 192 effective as commercially available violacein, with a mode of action that affects the actin 193 cytoskeleton of the parasite. We also tested 28 violacein analogue mixtures using a high-194 throughput growth assay on asexual parasites suggesting this method of biosynthetic 195 production is a suitable platform for antimalarial discovery and optimisation. 196
197
Previous work has shown that violacein is capable of killing lab-derived chloroquine-198 resistant P. falciparum parasites 14 . Here, we showed that patient-sourced clinical isolates, 199 sensitive or resistant to artemisinin, could equally be killed by both commercial and 200 biosynthetic violacein with similar IC50 values. Furthermore, although full IC50 curves could 201 not be generated, the compounds both inhibit development of the sexual stages of the 202 parasite life cycle with an IC50 of around 1.7 µM (Fig. S3 ). Any compound identified using 203 this assay with an IC50 of less than 2.0 µM is considered for further compound 204 development 26 . Combined, these data suggest violacein is a potential drug that could be 205 developed to antagonize resistance in the field and target both asexual and sexual stage 206 parasites. Whilst the derivative library tested consisted of mixtures of violacein analogues, it 207 is encouraging to see some of these compound mixtures have considerably more potent 208 anti-malarial activity than violacein itself. Critically, when we tested a purified compound (7-209 chloroviolacein) we saw a noticeable reduction in IC50 (0.51 µM to 0.42 µM), illustrating the 210 potential of biosynthetic production of antimalarial compounds for rapid screening and 211 rational drug optimisation. 212 213 Interestingly, violacein-treated parasites have cytoskeletal deformities that suggested 214 disruption to actin modulation within the parasite. Given violacein has no effect on actin 215 polymerisation kinetics in vitro, it is possible that the phenotype observed is as a result actin 216 aggregation in the cell, which could be a side effect of actin misfolding. P. falciparum 217 requires actin as an essential part of its motor complex and for other processes in the cell 9 .
Unlike most proteins, actin requires a dedicated chaperonin system to fold into its native 219 state 27 . Of note, this entire pathway is highly upregulated in artemisinin-resistant parasite 220 isolates 28 and would constitute a well-justified target for antagonising drug resistance in the 221 field. Further work in testing the effects of violacein on actin folding or modulation are 222 clearly required to explore whether this is the target for the drug. Ultimately, the ability of 223 violacein to affect such a major pathway as actin dynamics in the cell, as well as kill drug-224 resistant parasites, provides an encouraging outlook for its therapeutic development. 225
226
In summary, our data show that a bacterial biosynthetic platform for creating compounds 227 and their derivatives is suitable for testing for antimalarial drug development. As the need 228 for novel therapeutics increases and interest in natural compounds, often complex in 229 nature, grows we hope to use this approach to develop novel chemical scaffolds in a high 230 throughput manner towards finding the next generation of antimalarials. 231
232
METHODS 233
Generation and extraction of violacein and derivatives 234
Violacein and derivatives were generated and extracted as previously described 29 . Briefly, E. 235 coli JM109 strain (Promega) was transformed with the violacein pathway plasmid 236 (pTU2S(VioAE)-b-VioBCD) and grown overnight before being inoculated into LB broth until 237 OD600 reaches 0.5. These cultures were then supplemented with either tryptophan or a 238 synthetic tryptophan analogue at 0.04% (w/v) and grown at 25 o C for up to 65 h before 239 pelleted at 4000 rpm. The cell pellet was then resuspended with 1/10 th volume of ethanol to 240 extract violacein, followed by centrifugation to separate ethanol supernatant containing 241 violacein extract from cell debris. The supernatant was then dried in vacuo and stored at -20 242 °C for long-term storage or reconstituted in DMSO for growth inhibition assays. 243
Concentrations of violacein in the bacterial solvent extracts were calibrated against 244 commercial violacein standard (Sigma) based on absorbance at 575 nm. Compound 245 mixtures used in the growth inhibition assay consist of mixtures of violacein derivatives (Fig.  246 S4) as described previously 14 . 247
248 Plasmodium falciparum growth inhibition assays 249 P. falciparum parasite lines 3D7, ANL1, APL5G were used for the GIAs. The 3D7 sfGFP line 250 (G. Ashdown et al, manuscript in preparation) was used for immunofluorescence assays. All 251 parasite lines were cultured in complete RPMI (RPMI-HEPES culture media (Sigma) 252 supplemented with 0.05 g/L hypoxanthine, 0.025 g/L gentamicin and 5 g/L Albumax II 253 (ThermoScientific) and maintained at 1% to 5% parasitaemia and 4% haematocrit. For the 254 growth inhibition assay (GIA), 96-well plates were pre-dispensed with a serial dilution of 255 compound and normalised to 1% DMSO. Double-synchronised ring-stage parasites (1% 256 parasitaemia, 2% haematocrit, complete media, sorbitol synchronised at ring stage at 0 hrs 257 and 48 hrs) were added to the wells to a total volume of 101 µL. Cultures were incubated 258 for 72 h at 37 °C in a gas mixture of 90% N 2 , 5% O 2 , 5% CO 2 . Red blood cells were lysed 259 through freeze-thaw at -20 °C and parasites were resuspended and lysed with 100 µL lysis 260 buffer (20 mM TRIS-HCL pH 7.5, 5 mM EDTA, 0.008% saponin, 0.8% Triton-X 100) containing 261 0.2% SYBR green and incubated for 1 h at room temperature. SYBR green fluorescence 262 (excitation 485 nm / emission 535 nm) was measured using a Tecan infinite M200 Pro. Data 263 shown is the mean average of 3 biological replicates (± SEM), each of which is a mean 264 average of 3 technical replicates (unless stated otherwise), and is normalised to a positive 265 control (cycloheximide) and a negative control (DMSO only). IC50 values were calculated 266 using GraphPad Prism version 8.0. 267 268 Immunofluorescence assays 269 100 µL of mixed stage sfGFP parasite line (5% parasitaemia, 2% haematocrit) was incubated 270 for 24 h with 2 µM of the compound of interest. At t=0 h and t=6 h, parasites were fixed 271 with 4% paraformaldehyde, 2% glutaraldehyde (Electron Microscopy Sciences) and 272 incubated on a roller for 20 mins at room temperature (RT), before being pelleted at 3000 273 RPM and washed three times in 100 µL 1 X phosphate-buffered saline (PBS). The cells were 274 subsequently permeabilised in 0.1% Triton-X 100 (Sigma) for 10 mins at RT before being 275 pelleted and washed three times in PBS as before. Cells were blocked in 3% bovine serum 276 albumin (BSA) in PBS for 1 h at RT on a roller before being incubated with primary antibody 277
(1:500 mouse anti-actin 5H3 14 ) for 1 h at RT. Cells were washed three times with PBS before 278 addition of the secondary antibody (1:1000 anti-mouse Alexa 647 conjugated) for 1 h at RT. 279 Cells were washed three times in PBS and resuspended in 100 µL PBS with 0.05% DAPI. Cells 280 were diluted 30-fold and loaded onto polylysine-coated coverslips (ibidi) before being imaged. Imaging was performed on a Nikon Ti-E microscope using a 100 x Plan Apo 1.4 NA 282 oil objective lens with 'DAPI', 'FITC' and 'Cy5' specific filtersets. Image stacks were captured 283 3 µm either side of the focal plane with a z-step of 0.2 µm. Image analysis was conducted on 284 raw image data sets in ImageJ, calculating a ratio between AlexaFluor 647 and FITC by 285 measuring the mean signal intensity in a defined area of 88 nm 2 . 62 images were captured 286 for each sample from two wells from two biological repeats. Images shown in Fig. 4 were 287 deconvolved in Icy using the EpiDemic Plugin and a maximum intensity projection was made 288 in ImageJ. 
